The cell-based coagulation model was proposed 15 years ago, yet has not been applied commonly in the management of critical bleeding. Nevertheless, this alternative model may better explain the physiological basis of current coagulation management during critical bleeding. In this article we describe the limitations of the traditional coagulation protein cascade and standard coagulation tests, and explain the potential advantages of applying the cell-based model in current coagulation management strategies. The cell-based coagulation model builds on the traditional coagulation model and explains many recent clinical observations and research findings related to critical bleeding unexplained by the traditional model, including the encouraging results of using empirical 1:1:1 fresh frozen plasma:platelets:red blood cells transfusion strategy, and the use of viscoelastic and platelet function tests in patients with critical bleeding. From a practical perspective, applying the cellbased coagulation model also explains why new direct oral anticoagulants are effective systemic anticoagulants even without affecting activated partial thromboplastin time or the International Normalized Ratio in a dose-related fashion. The cell-based coagulation model represents the most cohesive scientific framework on which we can understand and manage coagulation during critical bleeding.
Introduction
Critical bleeding in the perioperative and intensive care setting is associated with significant mortality and morbidity 1, 2 . Traditionally, critical bleeding has been managed according to the coagulation blood test results such as the activated partial thromboplastin time (aPTT) and prothrombin time (PT) or International Normalized Ratio (INR) 3 , reflecting the intrinsic and extrinsic pathways of the coagulation plasma protein cascade respectively. Recent research suggests that this traditional plasma coagulation protein cascade model does not fully explain the clinical presentations of many coagulation disorders; nor have the aPTT and INR proved to be reliable in predicting bleeding or thrombosis 4, 5 . As such, alternative strategies, including use of empirical 1:1:1 fresh frozen plasma (FFP):platelets:red blood cells (RBCs) transfusion ratios 6 , viscoelastic point-of-care tests [7] [8] [9] , and selected platelet function tests [9] [10] [11] have been used in the management of critical bleeding. An alternative coagulation model, the cell-based coagulation model, was proposed 15 years ago, yet has not been applied commonly in the management of critical bleeding. Nevertheless, this alternative model may better explain the physiological basis of current coagulation management during critical bleeding. In this article we aim to describe the limitations of the traditional coagulation protein cascade and standard coagulation tests, and explain the potential advantages of applying the cell-based model in current coagulation management strategies.
Methods
We conducted a literature search using the following search terms: 'critical bleeding', 'cell-based model', 'transfusion'. We identified 5,468 human or animal original studies or review articles in the PUBMED database from its inception through to September 2016. Of these, 80 articles were considered relevant to our aim. Information from these articles is presented in this narrative review.
Limitations of the traditional plasma coagulation protein cascade and the standard coagulation parameters
The coagulation cascade has been traditionally considered as a process of sequential activation of plasma coagulation proteins through two distinct paths-the intrinsic and extrinsic pathways ( Figure 1 ) which converge at the final common pathway 12, 13 . This plasma coagulation protein cascade model explains how different plasma coagulation factors are activated and interact biochemically. It correlates well with the standard laboratory aPTT and INR assays. The aPTT measures the activity of the intrinsic (Factors XII, XI, IX, VIII) and common pathways (Factors X, V, II, I) of the coagulation cascade by incubating platelet-poor plasma at 37°C with a contact activator (e.g. micronised silica or ellagic acid) and phospholipid (e.g. cephalin). The time to form a fibrin clot after the addition of calcium is the measured aPTT. The PT (or INR in clinical practice) measures the activity of the extrinsic (Factor VII) and common pathways (Factors X, V, II, I) of the coagulation cascade by incubating platelet-poor plasma at 37°C with tissue factor (TF), phospholipid and calcium; PT is the time required for a fibrin clot to form in this test.
The traditional plasma coagulation protein cascade model suggests that the extrinsic and intrinsic pathways operate as semi-independent, distinct and redundant pathways, and the interactions between coagulation factors and cells are relatively limited. Although the INR and aPTT have been found to be extremely useful in assessing the anticoagulant effects of warfarin (a competitive antagonist to Factors II, VII, IX, X) and unfractionated heparin (which inactivates thrombin and Factor Xa through anti-thrombin III) 14 , some studies suggest that an elevated INR and aPTT in the absence of systemic anticoagulants may not be reliable as predictors of bleeding or thrombosis in many patients, including those with trauma, sepsis, or liver diseases 4, 5, 15, 16 . While the INR or PT and aPTT can tell us whether a platelet-poor plasma sample is deficient in one or more procoagulant factors in vitro, this may not necessarily be translatable to risk of bleeding (or thrombosis) in vivo. Under normal physiological conditions, the activities of endogenous procoagulants are counterbalanced by the activities of endogenous anticoagulants. Although the platelet-poor plasma used for INR and aPTT testing contains both endogenous procoagulants and anticoagulants (e.g. protein C reduces thrombin generation by inhibiting coagulation factors VIIIa and Va), the activation of the latter is limited without thrombomodulin from the endothelial cells 17 and hence, INR and aPTT may not reflect the bleeding or thrombotic risk in vivo accurately if there are changes in the endogenous anticoagulant system.
In addition to concentrations of both endogenous anticoagulants (e.g. protein C, protein S and antithrombin) 18 and procoagulants (e.g. hepatocyte tissue factor) 19 , other important factors that can also affect bleeding or thrombotic risk in vivo may include platelet count 20, 21 and status of the platelet activation (as evidenced by release of platelet microparticles and microRNAs) 22, 23 . Indeed, omission of pharmacological thromboprophylaxis due to a perceived increased risk of bleeding from an abnormal INR or aPTT has been reported to be associated with an increased risk of mortality 24, 25 , and FFP transfusion is not very effective in correcting an abnormal INR or aPTT in the critically ill or reducing risk of bleeding in patients with chronic liver disease 26, 27 . In patients with lupus anticoagulant, the aPTT is usually prolonged without an associated risk of bleeding or a deficiency in coagulation factors, solely as a result of the interaction between the lupus anticoagulant and the phospholipid activator (in low concentration) used in the aPTT assay 28 .
Even in hereditary disorders of coagulation factor deficiency, clinical observations do not support the independence of the intrinsic and extrinsic pathways, outlined in the traditional plasma coagulation protein cascade 29 . For instance, a deficiency in some coagulation factors such as factor XII, high-molecular-weight kininogen or pre-kallikrein in the early part of the intrinsic pathway is not associated with an increased risk of bleeding in humans or mice, despite a marked prolongation in aPTT 29 . Some mammalian species (such as whales and dolphins) also do not have a bleeding tendency despite their lack of factor XII 29, 30 . Furthermore, neither the intrinsic nor extrinsic pathway is sufficient in its own right in achieving haemostasis, with an isolated deficiency in Factor VIII (haemophilia A), Factor IX (haemophilia B), or Factor VII, each able to cause serious bleeding 31 . Inhibiting one single coagulation factor by oral direct anti-Xa (e.g. apixaban and rivaroxaban) and antithrombin (e.g. dabigatran) drugs is also sufficient to achieve systemic anticoagulation, but only with unpredictable and variable effects on INR and aPTT 32 . The traditional plasma coagulation protein cascade model is thus inadequate; Table 1 The limitations and utility of the standard coagulation blood tests and full blood count in patients with critical bleeding
Limitations: Utility:
Hereditary deficiency in some coagulation factors may cause an abnormal aPTT but not all such patients will have increased bleeding risk.
INR and aPTT are useful markers of the intensity of anticoagulant effects and whether further reversal is needed for patients with critical bleeding who are treated with warfarin and unfractionated heparin, respectively. 
Cell-based coagulation model
Those who have centrifuged blood samples to obtain plasma will note that plasma-with all its normal coagulation factors but without the blood cells (platelets and RBCs)does not form a solid clot without activating agents. In investigating the mechanisms of recombinant activated Factor VIIa in haemostasis, Hoffman et al found that activated Factor VIIa activates enough Factor X on activated platelets to restore platelet surface thrombin generation 37 . Hoffman et al hypothesised that localisation of Factor VIIa activity on the platelet surface would imply that the drug should only act at the site of tissue injury, which explains its safety and efficacy, as well as its haemostatic effect even in patients with thrombocytopenia and platelet function defects 37 .
They subsequently proposed a model in which coagulation is regulated by properties of cell surfaces, and coagulation occurs not as a cascade, but in three overlapping stages 38 . Initiation of coagulation first occurs on a TF-bearing cell; amplification occurs when a small quantity of coagulation factors and a limited number of platelets are activated; and propagation represents the final stage when thrombin burst occurs on the altered phospholipid membrane surface of activated platelets ( Figure 2 ).
In the cell-based coagulation model, the TF-bearing cells and platelets are the two key cell-related (or cellular) components, and thrombin and fibrinogen are the main coagulation proteins coordinating with these cell-related components to achieve haemostasis 29, [38] [39] [40] . The TF-bearing cells (such as vascular smooth muscle cells, adventitial fibroblasts and pericytes) are not normally in contact with plasma coagulation factors. Together with Factor VII, TF-bearing cells in the damaged vessel wall activate Factors X and IX at the site of injury triggering the initiation stage of coagulation. Factor Xa generates a small quantity of thrombin (in the amplification stage) which (i) strongly activates platelets through platelet protease-activated receptors (in particular PAR-4) resulting in expression of procoagulant phospholipids (phosphatidylserine and phosphatidylethanolamine) on the platelet membrane, shape-change (from discoid to an irregular sphere with long pseudopods to increase its surface area for interplatelet linkage) 41 , and activation of the glycoprotein IIb/IIIa receptors (allowing cross-linkage of platelets by fibrinogen) (Figure 3 ) 10,29,42 , (ii) activates part of the intrinsic pathway (by binding of Factor XI on platelet surface) including Factor IX and then Factor X, and subsequently (iii) activates Factors VIII and V allowing formation of Factors IXa/VIIIa complex and prothrombinase (Factors Xa/Va) complex (also on the surface of activated platelets), generating massive amounts of thrombin from prothrombin in the propagation stage of coagulation. Thrombin then activates more platelets and also Factor XIII (a fibrin stabilising factor), which links and stabilises fibrin polymers, as well as retaining RBCs to provide strength and stability to the blood clot (by forming a complex structure of RBCs, fibrin and platelet plug) 43 .
This cell-based coagulation model has a strong emphasis
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Initiation on TF-bearing cells and platelets and how they interact with different coagulation factors by acting as catalysts for their activation (resulting in a thousand-fold increase in the rate of reaction), and in return, thrombin provides a feedback loop to activate more platelets which are then aggregated by fibrinogen and von Willebrand factor. In addition, other recent studies suggest a third cellular element-the RBCsmay also be important by forming an impermeable complex polyhedral structure with platelets and fibrin to achieve haemostasis without vascular occlusion 44, 45 . This may explain why maintaining a certain threshold of haematocrit may potentially confer survival benefit in the most severe form of life-threatening critical bleeding 46 .
Critical bleeding and the cell-based coagulation model
While there is no strong evidence to show that using the cell-based coagulation model will directly improve patientcentred outcomes in critical bleeding compared to using the traditional coagulation protein cascade model (based on INR and aPTT alone), the cell-based coagulation model does explain some of the clinical observations that cannot be fully explained by the traditional plasma coagulation protein cascade. First, the standard INR test uses tissue factor to replace cellular components and phospholipid to replace platelets; it would not be measurable if these activators are not added to initiate and propagate the clotting process. Second, the importance of activated platelets in the clotting process, as highlighted in the cell-based model, is explained by the fact that inadequate platelet count or platelet activation (e.g. co-treatment with aspirin and clopidogrel) can impair generation of thrombin which, in turn, substantially reduces further activation of platelets resulting in increased risk of bleeding. Third, a low fibrinogen level not only affects fibrin formation but also affects the linkage and aggregation of activated platelets by the activated glycoprotein IIb/IIIa receptors 47 , explaining the emerging evidence about the importance of maintaining a normal fibrinogen concentration in critical bleeding 8, [48] [49] [50] . Similarly, high levels of uraemic toxins in patients with severe renal failure also contribute to a bleeding tendency through the same mechanism 51 , by reducing the affinity of the glycoprotein IIb/IIIa receptors to fibrinogen. In uraemic patients with critical bleeding, increasing von Willebrand factor by desmopressin (e.g. 0.3 μg/kg) may thus be considered to improve platelet adhesion and thrombus formation at bleeding sites with a high (arterial) shear rate 52 . Fourth, haemophilia A can induce severe bleeding even with an intact extrinsic pathway because there is an inadequate amount of Factor VIII to form Factors IXa/VIIIa complex on platelet surfaces to complete the propagation phase of coagulation. Finally, anti-Factor Xa drugs (such as direct Factor Xa inhibitors: apixaban, rivaroxaban, and to a lesser extent, the indirect Factor Xa inhibitor enoxaparin) reduce prothrombinase (Factor Xa/Va complex) on the surface of activated platelets, and antithrombin drugs (e.g. dabigatran) reduce activation of platelets by thrombin preventing further thrombin generation and platelet activation in the amplification and propagation stages of coagulation. Both classes of anticoagulants are very effective in the prevention and treatment of thrombosis despite inhibiting only one single plasma coagulation protein. Conversely, prothrombin complex concentratecontaining only coagulation Factors II, VII, IX, and X (note that Prothrombinex®-VF CSL-Behring used in Australia contains mainly only Factors II, IX and X with low level of Factor VII)appears to be as effective, if not more effective than FFP in supporting a thrombin burst and achieving haemostasis in clinical studies on critical bleeding 53, 54 , suggesting that some coagulation factors are more important than others in achieving haemostasis.
Empirical 1:1:1 RBCs:platelets:FFP transfusion and the cell-based coagulation model
Fresh whole blood (including plasma and platelets within the same blood unit) has been used for management of severe haemorrhagic shock by military physicians since World War I 55 , but achieving leucodepletion without reducing platelets in fresh whole blood in a civilian setting is difficult 56 . The next most similar transfusion practice is to use a 1:1:1 (FFP:platelets:RBC) transfusion strategy. The liberal use of platelets and FFP with RBCs in critical bleeding is also known as the 'Copenhagen Concept' 57 . This strategy was supported initially by a validation study of ten patients presenting with severe uncontrolled bleeding, demonstrating that such a strategy resulted in normal clot strength in the viscoelastic point-of-care analyses in all patients, including those who had received over 15 litres of blood products 58 . In addition, in a before-and-after study on patients with ruptured abdominal aortic aneurysm, there was a suggestion that a high ratio of FFP and platelets to RBC transfusion was associated with a better 30-day survival (66% versus 44%, P=0.02) compared to patients managed according to the standard transfusion guidelines using laboratory coagulation parameters 59 Holcomb et al subsequently reported the outcomes of 466 massively transfused trauma patients, and noted that those receiving high ratios of both FFP and platelets to RBCs had the highest survival rate 60 . A recent multicentre randomised controlled trial (RCT) (n=680) also showed that although the 1:1:1 transfusion strategy did not reduce all-cause mortality, it did improve anatomic haemostasis and reduce deaths as a result of exsanguination within the first 24 hours of trauma admission (a priori outcome of interest) compared to a 1:1:2 transfusion strategy (9.2% in the 1:1:1 group versus 14.6% in the 1:1:2 group; absolute difference = -5.4%, 95% confidence interval −10.4% to −0.5%, P=0.03) 6 . Because patients with critical bleeding who were managed with the 1:1:1 strategy in this trial would have received more platelets and fibrinogen (in addition to other coagulation factors), the results of this study indirectly support the cell-based coagulation model, as both blood components are considered as key elements in achieving haemostasis according to the cellbased coagulation model. The 1:1:1 transfusion strategy is currently recommended by the American College of Surgeons in the management of critical bleeding due to major trauma (https://www.facs.org/~/media/files/quality%20programs/ trauma/tqip/massive%20transfusion%20in%20trauma%20 guildelines.ashx). Finally, an additional benefit of this strategy is an indirect reduction in the use of crystalloid fluid, potentially reducing tissue oedema and facilitating abdominal wound closure after damage control surgery in patients with severe abdominal injuries 61 .
Viscoelastic tests and the cell-based coagulation model
The aPTT and INR assess coagulation factor activity in vitro using platelet-poor plasma only. In contrast, viscoelastic tests (e.g. thromboelastography, thromboelastometry) measure the clotting process in whole blood. While not specific for the cell-based model, these viscoelastic tests have the capacity to assess the activities of both coagulation factors and platelets, and have proved useful in the management of critical bleeding. In a systematic review of 11 RCTs involving 1,089 cardiac surgical patients 62 , the use of viscoelastic tests was associated with a reduction in RBC, FFP and platelet transfusion, but not fibrinogen transfusion, compared to using standard coagulation blood tests alone. The plasma fibrinogen concentration is often the first coagulation factor to reduce to a pathological low level in critical bleeding 63 , and it is also a major determinant of the thickness of the viscoelastic test tracing (e.g. maximal amplitude) 4, 8 . In this way, the thickness can be used to guide correction of fibrinogen levels with fibrinogen concentrate or cryoprecipitate if they are used to manage critical bleeding, although laboratory measurement of plasma fibrinogen concentration would be more accurate and specific as the thickness of viscoelastic tracing is also influenced by platelets. This may explain why fibrinogen usage was not reduced when viscoelastic tests were used to guide transfusion compared to the controls in the RCTs, and using fibrinogen transfusion as a first-line therapy to maintain a thick viscoelastic tracing was associated with a reduction in blood loss and RBC transfusion in critical bleeding 49, 50, 64 . An improvement in bleeding and transfusion outcomes by maintaining a thick viscoelastic test tracing (by transfusing platelets, fibrinogen, or both) is thus consistent with the important roles of platelets and fibrinogen emphasised in the cell-based coagulation model 29, 38, 40, 65 . Whether maintaining plasma fibrinogen concentrations well above the lower limit of normal, compared to just above the lower limit of normal (e.g. >2 g/l or 0.06 μmol/l), will improve outcomes of patients with critical bleeding remains unknown, but this merits further investigation.
Use of platelet function testing and the cell-based coagulation model
Although the thickness of a viscoelastic test tracing is useful in reflecting platelet-fibrinogen interaction, it is not reliable in detecting platelet adhesion defects (due to either congenital or acquired von Willebrand disease unless the test is modified with ristocetin) 66 , or platelet dysfunction Table 2 The limitations and utility of viscoelastic testing, such as thromboelastography (TEG®) and thromboelastometry (ROTEM®), and platelet function tests in patients with critical bleeding
Limitations: Utility:
Viscoelastic testing does not detect the effects of hypothermia on coagulation factor activity and platelet dysfunction when the sample is measured at 37°C.
Viscoelastic testing can detect the effect of glycoprotein IIb/IIIa antagonists (e.g. tirofiban) by showing a thinner tracing, because the action of these receptors is further downstream from thrombin's activities on the platelets.
Viscoelastic testing, as in ROTEM or TEG6s, does not detect the effect of hypocalcaemia on clot strength and platelet function when citrated blood samples are used for analysis.
The difference in the r-time in TEG or CT in ROTEM between heparinase and non-heparinase channels reflects the effects of unfractionated heparin, enoxaparin, or danaparoids and can be used to adjust the doses of protamine to reverse the anticoagulant effect of unfractionated heparin.
Viscoelastic testing does not measure platelet adhesion (e.g. von Willebrand disease) or platelet aggregation problems.
The r-time on TEG has a relatively linear relationship with plasma dabigatran concentrations in vitro, with measurable changes in the r-time even with plasma dabigatran concentration at 50 ng/ml (mean 7.4 min, 95% CI 6.7-7.2 vs control 6.0 min, 95% CI 5.2-6.7)(plasma concentration reaches a maximum at around 250 ng/ml +/-70 SD at 2 hours after taking dabigatran at a dose of 150 mg twice daily) 81 , potentially useful to guide the use of specific dabigatran reversal agent (e.g. idarucizumab).
Viscoelastic testing does not detect the effects of aspirin and clopidogrel (unless a TEG PlateletMapping® module is used), because the activator used in viscoelastic testing would generate enough thrombin to activate phospholipase C (the dominant platelet activation pathway) overriding the inhibition of minor platelet activation pathways through the P 2 Y 12 adenosine disphosphate receptors and cyclooxygenase-1.
The CT in the LowTF-ROTEM appears to correlate linearly with the increasing plasma concentrations of oral anti-Factor Xa agents (e.g. apixaban and rivaroxaban), offering a possible quick and reliable alternative to plasma anti-Factor Xa activities in assessing the anticoagulant effect of oral anti-Factor Xa agents 82 .
A deficiency in coagulation factors or presence of some systemic anticoagulants (e.g. without using heparinase in the presence of unfractionated heparin, enoxaparin, or danaparoids) will prolong the r-time in TEG or clotting time in ROTEM and, at the same time, reduce the maximum amplitude or maximum clot firmness, respectively.
Viscoelastic testing may detect fibrinolytic activity, potentially helpful to limit the use of antifibrinolytics only for patients who may benefit from these drugs.
Thrombocytopenia can produce results similar to platelet dysfunction in some platelet function tests (e.g. Multiplate® and PFA-100®) due to reduced amount of platelets aggregated over time, and some platelet function tests can be affected by haematocrit (e.g. PFA-100). due to antiplatelet agents, sepsis or severe trauma 10, 34, 35 . Nevertheless, recent studies suggest that measuring platelet function in whole blood may be useful in predicting blood loss and guiding platelet transfusion in cardiac surgery, as many cardiac surgical patients are treated with one or more antiplatelet agents before surgery 11, [67] [68] [69] . Even in the absence of antiplatelet medications, platelet dysfunction without thrombocytopenia has been observed in an animal model of haemorrhagic shock 70 , and this phenomenon appears to be most prevalent in severely injured patients with acidosis and traumatic brain injury 71 . Because platelets play a pivotal role in haemostasis according to both models of coagulation, an ability to exclude platelet dysfunction-which may occur in the absence of antiplatelet medications-would appear to be beneficial in the management of cardiac surgical or trauma patients with critical bleeding 34, 67, 68 .
There are currently many different methods to measure platelet function, including tests that assess the effect of platelet aggregation on electrical impedance (e.g. Multiplate®) or photo-transmission, and platelet adhesion under shear stress (e.g. PFA-200®) 10, 72 . In addition to documenting the presence of platelet dysfunction, some platelet function tests also have the capacity to quantify the severity of platelet dysfunction or degree of inhibition by antiplatelet drugs, usually by comparison to patients with normal platelet function 72 . Using different platelet activators, such as arachidonic acid, adenosine diphosphate, or thrombin receptor activating peptide, some platelet function tests (e.g. TEG PlateletMapping® or Multiplate) can define the precise mechanism of platelet inhibition (aspirin versus clopidogrel versus glycoprotein IIb/IIIa inhibitors) allowing clinicians to determine whether any ongoing bleeding is influenced by a residual effect of antiplatelet therapy 72 . The information derived from platelet function tests thus supplements those derived from viscoelastic tests and standard coagulation blood tests, potentially enabling clinicians to determine the underlying mechanism of bleeding in a more patient-specific or individualised fashion. Even for patients who refuse blood products including platelet transfusion (e.g. Jehovah's Witnesses), platelet function tests may still be useful to guide subsequent medical therapy in critical bleeding. As an off-label indication, recombinant activated factor VIIa may potentially reverse the antiplatelet effect of P 2 Y 12 inhibitors (e.g. prasugrel and clopidogrel) in a non-competitive fashion in patients with critical bleeding 37, [73] [74] [75] . Clinicians should be aware that thrombocytopenia may produce a platelet function test result similar to platelet dysfunction or inhibition by antiplatelet agents 34 , thus all platelet function test results must be interpreted simultaneously with the platelet count. The limitations and utility of viscoelastic tests and platelet function tests in critical bleeding are summarised in Table 2 
Discussion
By reflecting the quantities and activities of many coagulation factors in vitro, INR and aPTT will remain useful and, hence clinically relevant, to clinicians who manage critical bleeding. It has to be emphasised that many important therapies for critical bleeding remain unchanged, including urgent adequate source control, early empirical use of intravenous tranexamic acid 83, 84 , and maintaining normothermia, normal acid base status, and normocalcaemia 2,3,76-78 , regardless of whether we use the coagulation cascade or cell-based coagulation model as a framework to manage critical bleeding. Nevertheless, the cell-based coagulation model represents the most cohesive scientific framework on which we can understand critical bleeding and builds on the traditional coagulation protein cascade model. It also offers an alternative theoretical framework by highlighting the pivotal interactive roles of cells and coagulation factors, especially between TF-bearing cells, platelets, thrombin, and fibrinogen.
The cell-based coagulation model also appears to explain and support many recent clinical observations and research findings related to critical bleeding, including the encouraging results of using an empirical 1:1:1 FFP:platelets:RBC transfusion strategy 6 , and the use of viscoelastic and platelet function tests in patients with critical bleeding. From a practical perspective, applying the cell-based coagulation model will support (i) the use of an empirical 1:1:1 transfusion strategy in the most severe form of critical bleeding before coagulation and full blood count results are available, (ii) use of viscoelastic tests to guide fibrinogen and platelet transfusion, and (iii) the use of selected platelet function tests to exclude platelet dysfunction and guide platelet transfusion in patients treated with antiplatelet agents or when platelet dysfunction is suspected 6, 85, 86 . The standard full blood count and coagulation tests, especially the platelet count and plasma fibrinogen concentration respectively, will remain highly relevant and should form part of a comprehensive management protocol for patients with life-threatening critical bleeding, regardless of whether we adopt the cell-based coagulation model or traditional coagulation cascade framework ( Figure 4 ). Finally, emerging evidence, albeit weak at this stage, suggests that prothrombin complex concentrate transfusion 53, 54 , maintaining a higher haematocrit [44] [45] [46] , and monitoring thrombin generation (using platelet-rich plasma or whole blood instead of platelet-poor plasma) 87 may also be useful in optimising haemostasis in critical bleeding. The clinical benefits of these new strategies require further investigation before they can be incorporated as part of a standard transfusion protocol, but there is already sufficient rationale to consider these strategies in the management of critical bleeding.
